Stay updated on ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial
Sign up to get notified when there's something new on the ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial page.

Latest updates to the ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedA new history entry on 2026-02-18 updates the Study Status. The 2026-01-12 version was removed from the history.SummaryDifference0.3%

- Check16 days agoChange DetectedAdded a new revision entry (v3.4.2) to the study record history. The notice about government funding status and the older revision entry (v3.4.1) were removed.SummaryDifference0.7%

- Check23 days agoChange DetectedAdded a government funding lapse notice at the top of the page. Updated the site version from v3.4.0 to v3.4.1, removing the previous version reference.SummaryDifference0.7%

- Check30 days agoChange DetectedUI changes add a glossary toggle and color-coded highlights for additions (green) and deletions (red). The page shows a new revision label (v3.4.0) replacing the previous version (v3.3.4).SummaryDifference0.8%

- Check44 days agoChange DetectedAdded Study Status entries dated 2026-01-12 and 2026-01-09 with Revision: v3.3.4; removed the 2025-10-03 entry and Revision: v3.3.3 from the history.SummaryDifference0.4%

- Check65 days agoChange DetectedFooter updated to show Revision: v3.3.3, and references to HHS Vulnerability Disclosure and Revision: v3.3.2 were removed.SummaryDifference0.2%

Stay in the know with updates to ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ASTX727, Venetoclax, Gilteritinib in FLT3-Mutated AML Clinical Trial page.